High-Efficacy Therapy Cuts Disability Progression in Pediatric MS
By Elana Gotkine HealthDay Reporter
FRIDAY, April 12, 2024 -- Treatment of pediatric-onset relapsing-remitting multiple sclerosis with high-efficacy therapy reduces the risk for transition across disability states, according to a study published in the May issue of The Lancet Child and Adolescent Health.
Sifat Sharmin, Ph.D., from the University of Melbourne in Australia, and colleagues examined how high-efficacy therapies influence transition across five disability states in individuals with pediatric-onset multiple sclerosis. Data were included from 151 centers across 41 countries. People with onset of multiple sclerosis symptoms at younger than 18 years were included if they had a confirmed diagnosis of relapsing-remitting multiple sclerosis and at least four Expanded Disability Status Scale scores recorded. Overall, 5,224 patients were included.
The researchers observed a reduction in the risk for disability worsening across the disability states with high-efficacy therapies. Compared with those who remained untreated, those treated with high-efficacy therapies while in the minimal disability state had the largest reduction (hazard ratio, 0.41). There was a decline seen in the benefit of high-efficacy therapies with increasing disability. Compared with those who remained untreated, young people with minimal disability who received low-efficacy therapy also experienced a reduced risk for transitioning to mild disability (hazard ratio, 0.65).
"The new perspective presented here on the effect of early high-efficacy therapies for preserving neurological function among people with pediatric-onset multiple sclerosis provides a useful addition to the information guiding policy governing access to disease-modifying therapies in children with multiple sclerosis," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
Generic Medications Can Keep OOP Costs Down for Neurological Conditions
WEDNESDAY, Oct. 30, 2024 -- Generic medications reduce the out-of-pocket (OOP) costs for common neurological conditions, apart from multiple sclerosis, for which costs continue to...
Cognitive Therapy, Modafinil, Combo All Beneficial for Multiple Sclerosis Fatigue
FRIDAY, Oct. 25, 2024 -- Cognitive behavioral therapy (CBT), modafinil, and their combination are equally beneficial for multiple sclerosis fatigue, according to a study published...
Cancer Incidence Increased for People With Multiple Sclerosis
WEDNESDAY, Oct. 9, 2024 -- Cancer incidence is increased overall in people with multiple sclerosis (PwMS), with considerable differences depending on cancer type, age, and sex...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.